Kane Biotech

Kane Biotech Debt

The Debt of Kane Biotech (KNE.V) as of Oct 20, 2026 is 617,159.00 CAD. In the previous year, Debt was 958,238.00 CAD — a change of -35.59% (lower).

Debt

617,159.00CAD

YoY

-35.59%

Last updated:

In 2025, Kane Biotech's total debt was 617,159.00 CAD, a -35.59% change from the 958,238.00 CAD total debt recorded in the previous year.

The Kane Biotech Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
500,000.00 CAD
Jan 1, 2019
169,815.00 CAD
Jan 1, 2020
2.25 M CAD
Jan 1, 2021
4.71 M CAD
Jan 1, 2022
6.86 M CAD
Jan 1, 2023
9.21 M CAD
Jan 1, 2024
958,238.00 CAD
Jan 1, 2025
617,159.00 CAD
The Kane Biotech Debt history
YEARDebtYoY
617,159.00CAD-35.59%
958,238.00CAD-89.60%
9.21 MCAD+34.34%
6.86 MCAD+45.43%
4.71 MCAD+109.56%
2.25 MCAD+1,224.93%
169,815.00CAD-66.04%
500,000.00CAD-845.46%
-67,073.00CAD-113.97%
479,996.00CAD+9.43%
438,649.00CAD-2.20%
448,505.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kane Biotech Stock analysis

What does Kane Biotech do? Kane Biotech, Inc. generates revenue through its portfolio of biotechnology products designed to prevent and remove microbial biofilms. The company commercializes StrixNB, DispersinB, Aledex, bluestem, silkstem, goldstem, coactiv+, and DermaKB Biofilm, with specific focus on the Wound Care & Surgical division developing DispersinB for chronic wound care. The bluestem product line targets animal health markets with water additives, chews, spray, and dental wipes, while Coactiv+ and DispersinB Gel are in development for antimicrobial wound rinse and prosthetic joint infection applications. Additional products include Scalp Detoxifier, Shampoo, and Shampoo Bars for consumer use. Kane Biotech serves animal health markets through its bluestem product line, which includes water additives, chews, spray, and dental wipes. The Wound Care & Surgical division targets medical applications, focusing on DispersinB for chronic wounds and developing Coactiv+ for antimicrobial wound rinse and surgical hydrogel. Consumer products like Scalp Detoxifier, Shampoo, and Shampoo Bars cater to personal care segments. The company's development-stage products such as Coactiv+ antimicrobial surgical hydrogel and DispersinB Gel for prosthetic joint infection represent future revenue streams. The company's primary markets include animal health for bluestem products, medical applications for Wound Care & Surgical division, and consumer personal care for Scalp Detoxifier and Shampoo products. DispersinB is central to the medical division, while bluestem dominates the animal health segment. Development-stage products like Coactiv+ and DispersinB Gel are positioned to address unmet needs in wound care and prosthetic infections, expanding the company's market reach into specialized medical and consumer health segments. Kane Biotech is one of the most popular companies on Eulerpool.

Debt Details

Understanding Kane Biotech's Debt Structure

Kane Biotech's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Kane Biotech's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Kane Biotech’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Kane Biotech’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Kane Biotech stock

Debt of Kane Biotech is 617,159.00 CAD in 2025.

Debt of Kane Biotech changed from 958,238.00 CAD to 617,159.00 CAD, representing a -35.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Kane Biotech since 2006 – with annual values, charts, and detailed analysis.

Debt's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Kane Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Kane Biotech

All Key Metrics — Kane Biotech